[Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients].

Andrea Rodríguez Esquíroz, Lorea Sanz Álvarez, Marta Marín Marín, Patricia García González, Paula Aldave Cobos, Javier Garjón Parra
{"title":"[Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients].","authors":"Andrea Rodríguez Esquíroz, Lorea Sanz Álvarez, Marta Marín Marín, Patricia García González, Paula Aldave Cobos, Javier Garjón Parra","doi":"10.23938/ASSN.1056","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The oral antiviral nirmatrelvir/ritonavir interacts with a range of drugs. Candidate patients to receive this antiviral agent are usually vulnerable, multipathological and polymedicated. The objective is to evaluate the pharmaceutical validation prior to the administration of the antiviral.</p><p><strong>Material and methods: </strong>Drug-drug interactions between nirmatrelvir/ritonavir and patients' usual treatment medications were checked in product information and in the UpToDate® and the University of Liverpool® interaction tools. We included validated prescriptions between April/2022 and April/2023 by a Primary Care pharmacist.</p><p><strong>Results: </strong>Of the 159 study patients, 168 interactions were found in 83 individuals, which may have led to changes of their usual treatment. Statins (25.6%), anticoagulants (10.7%), and antihypertensives (10.7%) were the most frequently implicated therapeutic groups. Discontinuation (53.0%) and dose reduction (22.6%) were the most common treatment changes.</p><p><strong>Conclusions: </strong>Our search of potential drug interactions and subsequent dose adjustments and modifications of the patient's usual treatment has helped avoid potential toxicities ensuring a safe use of nirmatrelvir/ritonavir.</p>","PeriodicalId":500996,"journal":{"name":"Anales del sistema sanitario de Navarra","volume":"46 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807205/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales del sistema sanitario de Navarra","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23938/ASSN.1056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The oral antiviral nirmatrelvir/ritonavir interacts with a range of drugs. Candidate patients to receive this antiviral agent are usually vulnerable, multipathological and polymedicated. The objective is to evaluate the pharmaceutical validation prior to the administration of the antiviral.

Material and methods: Drug-drug interactions between nirmatrelvir/ritonavir and patients' usual treatment medications were checked in product information and in the UpToDate® and the University of Liverpool® interaction tools. We included validated prescriptions between April/2022 and April/2023 by a Primary Care pharmacist.

Results: Of the 159 study patients, 168 interactions were found in 83 individuals, which may have led to changes of their usual treatment. Statins (25.6%), anticoagulants (10.7%), and antihypertensives (10.7%) were the most frequently implicated therapeutic groups. Discontinuation (53.0%) and dose reduction (22.6%) were the most common treatment changes.

Conclusions: Our search of potential drug interactions and subsequent dose adjustments and modifications of the patient's usual treatment has helped avoid potential toxicities ensuring a safe use of nirmatrelvir/ritonavir.

[初级保健门诊患者中的尼马瑞韦/利托那韦药物相互作用]。
背景:口服抗病毒药物尼马瑞韦/利托那韦会与一系列药物相互作用。接受这种抗病毒药物的候选患者通常是易感、多病理和多药患者。我们的目标是在使用抗病毒药物前对药物验证进行评估:在产品信息以及 UpToDate® 和利物浦大学®交互工具中检查了 Nirmatrelvir/ritonavir 药物与患者常用治疗药物之间的交互作用。我们纳入了 2022 年 4 月至 2023 年 4 月期间由初级保健药剂师开具的有效处方:在 159 名研究对象中,有 83 人发现了 168 种相互作用,这可能会导致他们改变常规治疗方法。他汀类药物(25.6%)、抗凝药物(10.7%)和降压药(10.7%)是最常见的相互作用药物。停药(53.0%)和减量(22.6%)是最常见的治疗变化:我们对潜在的药物相互作用进行了搜索,随后对剂量进行了调整,并对患者的常规治疗进行了修改,这有助于避免潜在的毒性反应,确保了尼马瑞韦/利托那韦的安全使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信